We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NNDM:NASDAQNano Dimension Ltd. Analysis

Data as of 2026-05-26 - not real-time

$1.66

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Nano Dimension’s stock is trading just below its 20‑day simple moving average and slightly under the 50‑day SMA, with an RSI lingering in the mid‑40s, suggesting limited upward momentum. The MACD histogram is negative and the signal line is bearish, reinforcing a neutral‑to‑bearish short‑term bias. Beta is well above 1 and 30‑day volatility is approaching 70%, indicating the share price can swing sharply on new information. Volume trends are decreasing, which may exacerbate price swings in a thinly traded environment.
On the fundamentals side, revenue jumped over 100% year‑over‑year to roughly $30 million, driven largely by the Markforged acquisition, yet adjusted EBITDA widened to a $12.5 million loss, highlighting integration and margin pressures. The company holds a sizable cash buffer but continues to burn cash, and with a forward P/E near 166 versus an industry average under 40, the valuation appears stretched. No dividend is paid, and the balance sheet shows a modest debt load relative to cash. Overall, the stock looks overvalued given the earnings weakness, but a successful turnaround could unlock upside.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD and neutral trend
  • High volatility and decreasing volume
  • Recent earnings miss and widening loss

Medium Term

1–3 years
Neutral
Model confidence: 4/10

Key Factors

  • Revenue growth from acquisition
  • Continued cash burn and negative margins
  • Valuation still elevated relative to earnings

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • Potential upside if Markforged integration improves margins
  • Large cash position provides runway
  • Strategic exposure to additive manufacturing markets

Key Metrics & Analysis

Financial Health

Revenue Growth106.40%
Profit Margin-286.72%
P/E Ratio166.0
ROE-21.92%
ROA-7.29%
Debt/Equity6.27
P/B Ratio0.7
Op. Cash Flow$-100884000
Free Cash Flow$-59595376
Industry P/E39.5

Technical Analysis

TrendNeutral
RSI48.4
Support$1.49
Resistance$1.96
MA 20$1.70
MA 50$1.71
MA 200$1.69
MACDBearish
VolumeDecreasing
Fear & Greed Index91.8

Valuation

GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.86
Volatility69.56%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.